Combination treatment of osteoporosis: A clinical review

Journal of Women's Health and Gender-Based Medicine

Volumn 11, Issue 3, 2002, Pages 211-224

  Crandall, Carolyn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; CORTICOSTEROID; ESTRADIOL; ESTRADIOL VALERATE; ETIDRONIC ACID; FLUORIDE SODIUM; IBUTAMOREN; NANDROLONE DECANOATE; NORGESTREL; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT GROWTH HORMONE; SALCATONIN; TIBOLONE; VITAMIN D; FLUORIDE; GROWTH HORMONE;

ABDOMINAL DISTENSION; ANKLE EDEMA; ARTHRALGIA; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EPIGASTRIC PAIN; ESOPHAGITIS; FEMALE; FLUID RETENTION; FLUSHING; FOOD AND DRUG ADMINISTRATION; FRACTURE; GASTROINTESTINAL DISEASE; HAIR GROWTH; HIP; HOARSENESS; HUMAN; LEG EDEMA; LIVER DYSFUNCTION; LONG TERM CARE; LUMBAR SPINE; MASTALGIA; MEDICAL LITERATURE; METABOLIC DISORDER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NOSE IRRITATION; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UTERUS BLEEDING; WEIGHT GAIN; FRACTURE REDUCTION; OSTEOPOROSIS; POSTMENOPAUSE;

ALENDRONATE; BONE DENSITY; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036250596     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460902753668420     Document Type: Review

References (32)

1. Consensus development conference statement: Osteoporosis prevention, diagnosis, and therapy
2. Physician's guide to prevention and treatment of osteoporosis
3. Highlights of the conference
4. Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study
5. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: A placebo-controlled trial
6. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
7. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin
8. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
9. Treatment of osteoporosis with calcitonin, with and without growth hormone
10. Treatment of post-menopausal osteoporosos with recombinant human growth hormone and salmon calcitonin: A placebo controlled study
11. Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis
12. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate
13. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
14. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis
15. Three-year calcitonin combination therapy for post-menopausal osteoporosis with crush fractures of the spine
16. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin
17. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
18. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
19. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
20. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
21. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in post-menopausal osteoporotic women
22. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women
23. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in post-menopausal women with osteoporosis: A prospective, randomized study
24. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease
25. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
26. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone
27. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen
28. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium
29. Legumes and soybeans: Overview of their nutritional profiles and health effects
30. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women
31. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss